Content about Peripheral membrane proteins

October 17, 2013

The Food and Drug Administration has approved a new drug made by Novo Nordisk for treating hemophilia A, the Danish drug maker said.

BAGSVÆRD, Denmark — The Food and Drug Administration has approved a new drug made by Novo Nordisk for treating hemophilia A, the Danish drug maker said.

Novo Nordisk announced the approval of Novoeight (turoctocog alfa), a recombinant coagulation factor VIII, for adults and children with hemophilia, a disease caused by factor VIII deficiency that results in uncontrollable bleeding.

June 27, 2013

The Food and Drug Administration has approved what's being called the first therapy of its kind to prevent bleeding episodes.

SILVER SPRING, Md. — The Food and Drug Administration has approved what's being called the first therapy of its kind to prevent bleeding episodes.

The FDA announced Thursday the approval of Westlake Village, Calif.-based Baxter Healthcare Corp.'s Rixubis (coagulation factor IX [recombinant]) for patients with hemophilia B age 16 years and older. The treatment is used for controlling and preventing bleeding episodes, management of patients after surgery and routine use to prevent or reduce the frequency of bleeding episodes.

January 7, 2013

Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.

December 21, 2010

In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.

WESTON, Mass. and ZURICH — In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.

Among other assets, the agreement gives Biogen the worldwide rights to three preclinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system targets: alpha-synuclein, tau and TDP-43.

October 31, 2010

The U.S. subsidiary of a Swiss biotech company has started a late-stage trial of a...